Bulletin
Investor Alert

New York Markets After Hours

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

After Hours

/zigman2/quotes/207821052/composite

$

21.78

Change

+0.17 +0.79%

Volume

Volume 53,857

Sep 29, 2020, 5:10 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Today's close

$ 21.22

$ 21.61

Change

+0.39 +1.84%

Day low

Day high

$21.08

$22.40

Open
Open: 21.15

52 week low

52 week high

$9.18

$25.56

Open

Market cap

$1.25B

Average volume

738,816

P/E ratio

N/A

Rev. per Employee

$144,237

EPS

-2.30

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. These Companies Are Seeking a Cure for Sickle Cell

    11:53 a.m. July 25, 2020

    - Barron's Online

  2. Intellia Therapeutics downgraded to neutral from outperform at Wedbush

    8:15 a.m. Feb. 14, 2020

    - Tomi Kilgore

  3. Intellia Therapeutics stock price target cut to $16 from $21 at Wedbush

    8:16 a.m. Feb. 14, 2020

    - Tomi Kilgore

  4. Intellia Therapeutics upgraded to outperform from market perform at Raymond James

    7:44 a.m. Nov. 1, 2019

    - Tomi Kilgore

  5. CRISPR gene-editing technique set to push new boundaries

    9:10 a.m. Aug. 27, 2019

    - Jurica Dujmovic

  6. Intella Therapeutics upgraded to outperform from neutral at Wedbush

    8:28 a.m. May 3, 2019

    - Tomi Kilgore

  7. Gene-therapy stocks surge on Roche-Spark deal

    12:17 p.m. Feb. 25, 2019

    - Sarah Toy

  8. Intellia Therapeutics downgraded to neutral from outperform at Wedbush

    7:50 a.m. Nov. 2, 2018

    - Tomi Kilgore

  9. Intellia Therapeutics started at market perform at Raymond James

    8:27 a.m. Sept. 21, 2018

    - Tomi Kilgore

  10. CRISPR Technology Still Holds Big Promise

    3:13 p.m. Aug. 3, 2018

    - Barron's Online

  11. Gene-editing stocks tumble on concerns about DNA damage

    12:21 p.m. July 16, 2018

    - Emma Court

  12. Gene-editing stocks tumble on concerns about DNA damage

    12:13 p.m. July 16, 2018

    - Emma Court

  13. Gene-Editing Selloff Is Overdone

    2:20 p.m. July 11, 2018

    - Barron's Online

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. Intellia's gene editing platforms show encouraging action in preclinical studies

    11:43 a.m. Today

    - Seeking Alpha

  2. CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

    11:03 a.m. Sept. 23, 2020

    - Zacks.com

  3. Editas Medicine up 5% on favorable CRISPR/Cas9 patent ruling

    8:20 a.m. Sept. 11, 2020

    - Seeking Alpha

  4. CRISPR Stocks: Buy or Trade?

    5:26 p.m. Sept. 9, 2020

    - Zacks.com

  5. Seeking Alpha Catalyst Watch

    3:11 p.m. Aug. 14, 2020

    - Seeking Alpha

  6. CRISPR Therapeutics: My #1 High-Risk Investment Idea

    2:55 p.m. Aug. 14, 2020

    - Seeking Alpha

  7. Genomic Medicine: Summer 2020 Update

    9:36 a.m. Aug. 13, 2020

    - Seeking Alpha

  8. Intellia Therapeutics high post Q2 collaboration revenue growth

    10:51 a.m. Aug. 6, 2020

    - Seeking Alpha

  9. Notable earnings before Thursday's open

    1:25 p.m. Aug. 5, 2020

    - Seeking Alpha

  10. Loading more headlines...
/news/pressrelease/company/us/ntla

Press Releases on NTLA

  1. Loading more headlines...

Rates »

Link to MarketWatch's Slice.